Read More

Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says

Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho bullish with Buy rating, $34 price target. ELVN's trading value suggests conservative estimation compared to CML market potential.

ELVN